Opexa Therapeutics Reports Positive Top-line Data in Phase I/II ...
PipelineReview.com (press release) - Barcelona,Spain
The "per-protocol" analysis of Tovaxin therapy achieved a 92% reduction in annualized relapse rate (ARR) in subjects who received two treatment doses of 30 ...
See all stories on this topic

Opexa's MS vaccine cut relapse rates
United Press International - USA
THE WOODLANDS, Texas, June 21 (UPI) -- US firm Opexa Therapeutics said Thursday a phase 1/2 study of its multiple sclerosis vaccine Tovaxin cut relapse ...
See all stories on this topic

Researcher avoiding politics of fund
Journal and Courier - Lafayette,IN,USA
A drug called Fampridine is being tested by the Federal Drug Administration in humans and may be available for multiple sclerosis patients in a few years. ...
See all stories on this topic